Starting this week and over the coming months, the Pulmonary Fibrosis Foundation (PFF) will be hosting the PFF Walk…
Articles by Marisa Wexler, MS
Basal stem cells taken from the upper part of a patient’s respiratory tract can be expanded in the lab and…
Enrollment is now complete in a Phase 2b clinical trial, dubbed CORAL, that’s testing nalbuphine extended-release (ER) tablets — planned…
A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study…
Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with…
Mediar Therapeutics is planning to launch a Phase 2 clinical trial to test its experimental therapy MTX-463 in people…
CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in…
Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating…
In the U.K., patients with idiopathic pulmonary fibrosis (IPF) who live in economically deprived neighborhoods have worse survival outcomes…
Almee, a behavioral therapy app designed to help ease anxiety in people with pulmonary fibrosis (PF), has been granted…